ITeos Therapeutics (ITOS)

Company Profile

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity in the dose escalation portion of the trial. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

Company profile

Ticker

ITOS

Exchange

NASDAQ

Website

iteostherapeutics.com

CEO

Michel Detheux

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

SEC CIK

0001808865

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

iTeos Therapeutics S.A. • iTeos Securities Corporation • iTeos BE, LLC ...

ITOS stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

10 Nov 22

Correspondence with SEC

10 Aug 22

Submission of Matters to a Vote of Security Holders

12 May 22

Additional proxy soliciting materials

25 Apr 22

DEF 14A

Definitive proxy

25 Apr 22

Transcripts

ITOS

Earnings call transcript

2021 Q3

11 Nov 21

ITOS

Earnings call transcript

2021 Q2

13 Aug 21

ITOS

Earnings call transcript

2021 Q1

14 May 21

Latest ownership filings

View all

Hauwermeiren Timothy Van

Financial summary

Financial statements Chart ITOS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	752.47 mm	752.47 mm	752.47 mm	752.47 mm	752.47 mm	752.47 mm
Cash burn (monthly)	13.23 mm	12.29 mm	5.07 mm	(no burn)	9.90 mm	11.90 mm
Cash used (since last report)	53.88 mm	50.05 mm	20.64 mm	n/a	40.32 mm	48.48 mm
Cash remaining	698.59 mm	702.42 mm	731.82 mm	n/a	712.15 mm	703.98 mm
Runway (months of cash)	52.8	57.2	144.4	n/a	71.9	59.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

ITOS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	144	157	-8.3%
Opened positions	19	31	-38.7%
Closed positions	32	33	-3.0%
Increased positions	62	73	-15.1%
Reduced positions	34	32	+6.3%

13F shares	Current	Prev Q	Change
Total value	772.84 mm	880.86 mm	-12.3%
Total shares	38.27 mm	40.93 mm	-6.5%
Total puts	0.00	45.70 k	EXIT
Total calls	10.10 k	237.10 k	-95.7%
Total put/call ratio	–	0.2	–

Largest owners	Shares	Value	Change
Ra Capital Management	4.42 mm	$84.15 mm	0.0%
BLK Blackrock	4.32 mm	$82.24 mm	+16.0%
MPM Asset Management	2.74 mm	$52.17 mm	0.0%
Boxer Capital	2.15 mm	$41.04 mm	0.0%
Biotechnology Value Fund L P	1.93 mm	$56.33 mm	0.0%
MPM BioVentures 2014	1.84 mm	$59.33 mm	0.0%
BVF	1.81 mm	$34.50 mm	-6.1%
Vanguard	1.75 mm	$33.36 mm	+7.5%
MPM Oncology Impact Management	1.75 mm	$33.26 mm	0.0%
Citadel Advisors	1.32 mm	$25.18 mm	+85.2%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-2.48 mm	EXIT
Rubric Capital Management	0.00	-822.11 k	EXIT
Citadel Advisors	1.32 mm	+608.17 k	+85.2%
BLK Blackrock	4.32 mm	+595.92 k	+16.0%
Deutsche Bank AG - Registered Shares	16.37 k	-583.46 k	-97.3%
Alliancebernstein	72.78 k	-558.34 k	-88.5%
Jacobs Levy Equity Management	466.33 k	+466.33 k	NEW
Millennium Management	738.36 k	+413.66 k	+127.4%
EcoR1 Capital	40.48 k	-239.52 k	-85.5%
MS Morgan Stanley	833.89 k	-219.34 k	-20.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ITOS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Jun 22	Detlev Biniszkiewicz	Stock Option Common Stock	Grant	Acquire A	No	No	18.78	17,538	329.36 k	17,538
9 Jun 22	DiRocco Derek	Stock Option Common Stock	Grant	Acquire A	No	No	18.78	17,538	329.36 k	17,538
9 Jun 22	Davis Aaron I.	Stock Option Common Stock	Grant	Acquire A	No	No	18.78	17,538	329.36 k	17,538
9 Jun 22	Ho Tony W	Stock Option Common Stock	Grant	Acquire A	No	No	18.78	17,538	329.36 k	17,538
9 Jun 22	Robert Iannone	Stock Option Common Stock	Grant	Acquire A	No	No	18.78	17,538	329.36 k	17,538